BioNTech SE Sponsored ADR $BNTX Shares Sold by Canada Pension Plan Investment Board

Key Points

• The Canada Pension Plan Investment Board reduced its stake in BioNTech SE by 12.1% in the first quarter, owning approximately 0.07% of the company worth $16.19 million after the sale of 24,483 shares.
• BioNTech reported 102.6% year-over-year revenue growth in its recent quarterly earnings, totaling $306.46 million, although it missed EPS estimates and showed a negative net margin of 12.20%.
• Analysts maintain a consensus rating of "Moderate Buy" for BioNTech, with target prices ranging from $116 to $155, reflecting varied outlooks among analysts on the stock's future performance.

Canada Pension Plan Investment Board cut its holdings in BioNTech SE Sponsored ADR (NASDAQ:BNTX - Free Report) by 12.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 177,839 shares of the company's stock after selling 24,483 shares during the quarter. Canada Pension Plan Investment Board owned 0.07% of BioNTech worth $16,194,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. OneDigital Investment Advisors LLC purchased a new stake in shares of BioNTech in the first quarter valued at approximately $288,000. GAMMA Investing LLC boosted its position in BioNTech by 5,710.8% during the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after purchasing an additional 52,711 shares in the last quarter. Wealth Enhancement Advisory Services LLC purchased a new stake in BioNTech during the fourth quarter worth $238,000. Allianz Asset Management GmbH boosted its position in BioNTech by 44.3% during the first quarter. Allianz Asset Management GmbH now owns 120,680 shares of the company's stock worth $10,989,000 after purchasing an additional 37,075 shares in the last quarter. Finally, Cerity Partners LLC purchased a new stake in BioNTech during the first quarter worth $357,000. 15.52% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

A number of analysts have commented on BNTX shares. Leerink Partners set a $112.00 target price on BioNTech in a research report on Monday, June 2nd. Truist Financial reiterated a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. HC Wainwright dropped their price target on BioNTech from $138.00 to $136.00 and set a "buy" rating for the company in a research note on Thursday, August 14th. Wall Street Zen raised BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday, June 7th. Finally, Bank of America upped their target price on BioNTech from $126.00 to $134.00 and gave the stock a "buy" rating in a research report on Tuesday, August 5th. Thirteen investment analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus target price of $135.80.

BioNTech Stock Performance

Shares of NASDAQ BNTX traded up $8.96 during mid-day trading on Friday, hitting $112.46. The company had a trading volume of 2,052,527 shares, compared to its average volume of 669,941. The stock has a market cap of $27.04 billion, a price-to-earnings ratio of -70.29 and a beta of 1.39. BioNTech SE Sponsored ADR has a 12 month low of $81.20 and a 12 month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.61 and a quick ratio of 8.48. The firm's 50 day simple moving average is $109.49 and its two-hundred day simple moving average is $104.53.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, August 4th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($1.41) by ($0.19). BioNTech had a negative net margin of 12.20% and a negative return on equity of 1.84%. The business had revenue of $306.46 million during the quarter, compared to analyst estimates of $161.26 million. During the same quarter in the prior year, the business earned ($3.36) earnings per share. The firm's revenue was up 102.6% compared to the same quarter last year. BioNTech has set its FY 2025 guidance at EPS. As a group, equities research analysts forecast that BioNTech SE Sponsored ADR will post -3.88 earnings per share for the current year.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.